

# BMJ Open Multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira) as a novel treatment in patients with high-grade squamous intraepithelial lesion: APRICITY phase 3 study protocol

Fei Chen,<sup>1</sup> Zoltán Novák,<sup>2,3</sup> Christian Dannecker,<sup>4</sup> Ctirad Mokráš,<sup>5</sup> Long Sui,<sup>6</sup> Youzhong Zhang,<sup>7</sup> Zhixue You,<sup>8</sup> Ling Han,<sup>9</sup> Jinghe Lang,<sup>1</sup> Peter Hillemanns <sup>10,11</sup>

**To cite:** Chen F, Novák Z, Dannecker C, *et al*. Multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira) as a novel treatment in patients with high-grade squamous intraepithelial lesion: APRICITY phase 3 study protocol. *BMJ Open* 2022;**12**:e061740. doi:10.1136/bmjopen-2022-061740

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-061740>).

Received 08 February 2022  
Accepted 13 May 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Peter Hillemanns;  
hillemanns.peter@mh-hannover.de

## ABSTRACT

**Introduction** High-risk human papilloma virus (HPV)-associated cervical cancer is the fourth most common cancer in women worldwide. Current treatments of high-grade squamous intraepithelial lesion (HSIL) of the cervix are based on invasive surgical interventions, compromising cervical competence and functionality. APRICITY is a multicentre, prospective, double-blind, randomised controlled phase 3 study further evaluating the efficacy and safety of Cevira, an integrated drug-delivery and light-delivery device for hexaminolevulinate photodynamic therapy, which shows promise as a novel, non-invasive outpatient therapy for women with HSIL.

**Methods and analysis** Patients with biopsy-confirmed HSIL histology are invited to participate in the study planned to be conducted at 47 sites in China and 25 sites in Ukraine, Russia and the European Union. The aim is to include at least 384 patients, which will be randomised to either Cevira or placebo group (2:1). All patients will be assessed 3 months after first treatment and a second treatment will be administered in patients who are HPV positive or have at least low-grade squamous intraepithelial lesion. Primary endpoint is the proportion of the responders 6 months after first treatment. Secondary efficacy and safety endpoints will be assessed at 6 months, and data for secondary performance endpoints of the Cevira device will be collected at 3 months and 6 months, in case second treatment was administered. All patients in the Cevira group will be enrolled in an open, long-term extension study for 6 months to collect additional efficacy and safety data (study extension endpoints).

**Ethics and dissemination** The study was approved by the ethics committee of the Peking Union Medical College Hospital and Hannover Medical University, Germany. Findings will be disseminated through peer review publications and conference presentations.

**Trial registration number** NCT04484415; clinicaltrials.gov.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ APRICITY is a multicentre, prospective, double-blind, randomised controlled phase 3 trial, evaluating hexaminolevulinate photodynamic therapy (Cevira) in high-grade squamous intraepithelial lesion patients.
- ⇒ The study has an international setup, planning to include 47 sites in China and 25 sites in Ukraine, Russia and the European Union.
- ⇒ The most important limitation is the potential for spontaneous regression of CIN2 lesions in the placebo group, which could underestimate the trial results.

## INTRODUCTION

Cervical cancer is the fourth most common cancer in women worldwide, almost exclusively linked to infection with high-risk human papilloma viruses (HPV).<sup>1</sup> In 2020, 604 000 new cases and 342 000 deaths worldwide were attributed to cervical cancer. Of these new cases and deaths, about 90% are occurring in low-income and middle-income countries due to the lack organised screening.<sup>1 2</sup> In China, the most prevalent HPV subtypes are HPV16, 52 and 58, while in Europe HPV16, 31 and 33 are more common.<sup>3</sup> Notably, all mentioned HPV subtypes belong to the same alpha genotype.<sup>4</sup> There are at least 14 high-risk HPV subtypes identified, with HPV16 and HPV18 causing 70% of cervical cancers and precancerous lesions.<sup>3 5</sup>

HPV is transmitted during sexual intercourse with the highest prevalence among sexually active young women. In the vast majority (~90%), infection is spontaneously

cleared and induced low-grade squamous epithelial lesion (LSIL) or cervical intraepithelial neoplasia (CIN) 1 has low potential to develop into cervical malignancy. Nevertheless, a subset of patients is at risk to develop persistent HPV infection increasing the risk for progression to high-grade squamous intraepithelial lesion (HSIL) and eventually cancer.<sup>6 7</sup> Based on histopathological characteristics and the severity of dysplasia, HSIL can be subdivided into CIN2 and 3, corresponding to moderate and severe dysplasia, respectively.<sup>8 9</sup> Unlike LSIL which usually resolves spontaneously, the guidelines for cervical cancer screening generally recommend medical treatment for women with HSIL.<sup>10</sup> Although in women of childbearing age, CIN2 lesions often regress spontaneously, not requiring immediate intervention.<sup>11 12</sup>

Current treatment options for patients with HSIL include excisional and ablative treatment.<sup>13</sup> However, these surgical treatments may lead to perinatal complications, including preterm labour, low birth weight and perinatal death, limiting their use in women of reproductive age.<sup>14</sup> Surgical treatments lead to a success rate of 85%–95% in complete excision of the lesion.<sup>15</sup> Recurrences occur as precancerous conditions such as CIN2 or CIN3; however, there is an elevated risk for invasive cervical cancer as well.<sup>16 17</sup> To preserve cervical tissue functionality, repeated surgical interventions are not recommended but no good tissue alternatives are available for the treatment of high-grade CIN.

Non-invasive therapies have been developed for the treatment of HSIL and include topical agents (immune modulators, antiproliferative medications, antivirals, herbal regimens and probiotics), therapeutic vaccines and biologicals.<sup>18–20</sup> However, due to the lack of sufficient clinical evidence, none of them have been accepted by the American Society for Colposcopy and Cervical Pathology and European Federation for Colposcopy for the management of cervical cancer and precancerous lesions and surgical methods remain the standard of care.<sup>13 21</sup>

Due to the side effects associated with surgical treatments and the lack of evidence for most of the current non-invasive therapies, there has been a growing interest in non-invasive photodynamic therapy (PDT) using topically applied photosensitisers for the treatment of CIN.<sup>22–27</sup> PDT is based on the accumulation of a photosensitiser or its precursor in the target cells, which on illumination generates reactive oxygen species that eradicate the diseased cells by inducing apoptosis and necrosis while preserving the underlying stroma and thereby the functionality of the cervix.<sup>28</sup> For the treatment of CIN, topical hexaminolevulinate hydrochloride (HAL) has been mostly studied as photosensitiser showing promising efficacy and favourable safety results.<sup>25 26</sup> These initial results were confirmed in a Phase 2b study administering HAL as an ointment via an intravaginal photoactivation device (Cevira, Photocure ASA, Oslo, Norway).<sup>27</sup>

The objective of APRICITY phase 3 multicentre, prospective, randomised controlled trial (RCT) is

to further evaluate the efficacy and safety of Cevira compared with placebo in the treatment of patients with cervical histological HSIL (ie, CIN2/3).

## METHODS AND ANALYSIS

### Study design

The phase 3 study is designed as a multicentre, prospective, double-blind RCT enrolling patients with an adequate colposcopy and histology diagnosis of HSIL (clinicaltrials.gov Identifier: NCT04484415) (figure 1). Randomisation to either Cevira or placebo (2:1) is stratified by CIN diagnosis (CIN2 or CIN3) and HPV status (HPV-, HPV16+ or HPV18+Other+). Primary efficacy will be evaluated 6 months after first treatment for both groups. A second treatment will be administered in patients from both treatment groups who at the 3-month assessment have cytology of LSIL or more severe lesion (HSIL or atypical squamous cells-cannot exclude HSIL) or in patients who are HPV positive. Retreatment visit should be no later than 1 month after the 3-month assessment visit.

All patients in the Cevira group will be enrolled in an open, long-term extension study following patients for an additional 6 months. To minimise the risk to the patients in the placebo group, they will be unblinded after 6 months to complete the study. Patients with persistent high-grade CIN after 6 months will receive surgical treatment regardless of study group.

The study is planned to be conducted at 47 sites in China and 25 sites in Ukraine, Russia and the European Union (EU, including Hungary, Romania, Germany, Czech Republic, Slovakia, Poland and Netherlands).


### Study population

In the Phase 2b study, the efficacy of HAL PDT could only be demonstrated in CIN2 patients, probably due to the high spontaneous regression rate in the CIN1 population.<sup>27</sup> Based on this outcome, it was decided to only enrol patients with HSIL (CIN2/3) in the present phase 3 study.

### Eligibility criteria

#### Inclusion criteria

To be included, patients must have biopsy-confirmed HSIL histology determined by a panel of three pathologists from a central laboratory in each region (China, USA and Europe), not more than 2 months prior to the administration of Cevira or placebo. Colposcopy should visualise the entire lesion margin and entire cervical transformation zone, including the squamocolumnar junction, to demonstrate that the lesion covers more than 15% of the uterine cervix before biopsy. Additionally, the uterine cervix should have an average diameter of approximately 27 mm to allow application of Cevira. Only female patients aged 18 years and older (maximum age 85 years) will be included. Patients must use a highly effective method of contraception during the entire study and 30 days after study end. Sterilised women or



**Figure 1** Overview of the APRICITY phase 3 study design.

women who are post-menopausal for at least 1 year can be included without use of contraception.

#### Exclusion criteria

Key exclusion criteria are a total lesion area covering over 50% of the cervix (only for biopsy-confirmed CIN3), invasive cervical cancer, adenocarcinoma in situ or other glandular intraepithelial lesions and lesions extending to the cervical canal or vaginal vault. Of note, in certain countries (eg, Hungary), the ethical review board allowed only the inclusion of HSIL/CIN2 patients and excluded patients diagnosed with CIN3. Additional exclusion criteria are significant vaginal infection or bleeding, current severe pelvic inflammatory disease, history of toxic shock syndrome, known allergies to hexamino-levulinate and/or silicone, use of heart pacemaker and porphyria. Furthermore, patients must not be pregnant or breastfeeding.


Prior and during the entire study follow-up, patients are not allowed to use drugs or treatments that may affect efficacy evaluation, that is, drugs treating HPV, HSIL and tumours as well as regulating immunologic function. In addition, patients who previously received surgical treatment, have incomplete cervical structure and have recurrent HSIL or patients who received other treatment after the confirmed diagnosis of HSIL are excluded from the study. Furthermore, patients may not participate in other therapeutic clinical trials using investigational agents either concurrently or within the last 30 days. Finally,

patients are excluded if they are not deemed suitable in the investigator's opinion or if the patient has a conflict of interest that would interfere with the study conduct.

#### Interventions

Cevira is an integrated combination of 5% HAL in ointment and the drug delivery device Cevira CL7 (figure 2A). The drug is administered intravaginally to the cervix by a gynaecologist using the drug delivery device (figure 2B). The device is a single-use, disposable, LED-based integrated red light source used to photoactivate the drug. The device will automatically switch on the light 5 hours after administration and provide continuous photoactivation of 125 J/cm<sup>2</sup> over 4.6 hours before automatically shutting down. The device needs to be removed by the patient once the treatment has been completed between 11 and 24 hours after administration. The placebo ointment contains only vehicle and is similar in appearance and consistency to the Cevira ointment. The placebo device is identical in appearance as the Cevira CL7 device without providing light. The investigators and staff at each site are trained on at least five occasions in the study procedures before study starts through standard intervention procedure videos on which each investigator should perform the intervention before opening the study site.

Treatment in both Cevira or placebo group must be discontinued if any of the following occurs: consent withdrawal, substantial non-compliance, lost to follow-up, occurrence of a serious adverse event (SAE) possibly



**Figure 2** Cevira (Photocure ASA, Oslo, Norway). (A) Cevira CL7 drug delivery device with integrated red light source. (B) Ointment and device are administered intravaginally by the gynaecologist to the cervix of the HSIL patient. HSIL, high-grade squamous intraepithelial lesion.

related to study treatment, investigator's concern for the patient's health, pregnancy or intention to become pregnant or the investigator's decision to use other appropriate treatments due to disease progression. The patient may request withdrawal due to an adverse event (AE) for which the investigator did not consider removal from the study necessary.

### Outcomes

The primary endpoint is the proportion of the responders at 6 months after the first treatment, with response being defined as normal histopathology or LSIL histopathology with clearance of baseline HPV. The list of secondary efficacy endpoints, study extension endpoints and safety endpoints is found in [box 1](#).

### Assessments

Study flow and follow-up of assessments are shown in [figure 3](#). The primary and secondary efficacy assessments will be done 6 months after the first treatment and will be based on histology and clinically validated testing for HPV (Cobas, Roche). To standardise the procedure, investigators will all receive a colposcopy operation manual. Colposcopy-directed biopsies will be obtained from all colposcopically suspicious areas. If there is a normal colposcopy at 6 months or at assessment of study extension endpoints at 12 months, biopsies will be obtained from the original baseline affected area(s) to confirm histologic regression. Two pathologists will independently review the slide(s) from each biopsy in a blinded manner. If there is a discrepancy between the biopsy diagnosis, a third pathologist will review the slide(s). Clinically validated testing of cytology (ThinPrep, Hologic) and HPV



## Box 1 Secondary efficacy, study extension and safety endpoints of the APRICITY phase 3 study

### Secondary efficacy endpoints

1. The proportion of HPV+ patients with clearance of baseline HPV at 6 months after the first treatment.
2. The proportion of HPV16+ patients with clearance of HPV16 at 6 months after the first treatment.
3. The proportion of HPV16+ and/or HPV18+ patients with clearance of baseline HPV at 6 months after the first treatment.
4. The proportion of patients with histologic regression, defined as LSIL or normal histology, at 6 months after the first treatment.

### Secondary performance/usability endpoints

1. The proportion of gynaecologists successfully inserting the device within 15 min.
2. The proportion of patients with device dislocation or slippage during treatment.
3. The proportion of patients removing the device outside the specified time.

### Study extension endpoints

1. The proportion of patients who had LSIL histology and non-clearance of baseline HPV at 6 months, who became responders at 12 months after the first treatment.
2. The proportion of responders at 6 months who have continued regression at 12 months after the first treatment.

### Safety endpoints

1. The proportion of patients with AEs up to 6 months after the first treatment.
2. The proportion of patients with Cevira 5% HAL ointment-related AEs up to 6 months after the first treatment.
3. The proportion of patients with Cevira CL7 device-related AEs up to 6 months after the first treatment.
4. The proportion of device deficiencies.
5. The proportion of patients in the treatment group with AEs up to 12 months after the first treatment.

AE, adverse event; HAL, hexaminolevulinate hydrochloride; HPV, human papilloma virus; LSIL, low-grade squamous intraepithelial lesion.

(Cobas, Roche) will be used to determine the need for a second treatment.

The secondary performance assessment will be based on the number of gynaecologists successfully inserting the device within 15 min, the number of patients with device dislocation or slippage during treatment and the number of patients removing the device outside the specified time. Data will be collected using a patient diary and assessed at 3 months and at 6 months, in case a second treatment was applied. Safety endpoints assessment will be done at 6 months after first treatment. No interim analysis is planned for this study.

Within 24 hours of Cevira administration, the patients will be contacted telephonically by study personnel, to ensure correct handling of the device and for a safety check. A mandatory patient diary will be used to record the time of device removal and possible AE during use and/or after removal of the Cevira device. To ensure treatment compliance, regular reminders will be provided to the patients to complete the follow-up visits as scheduled.

## Statistical consideration

### Sample size

The sample size calculation is based on the efficacy results for the HSIL histology population from the phase 2b study using a significance level of 5%.<sup>27</sup> It is assumed that the proportion of patients who will achieve response is 60% in the Cevira group and 40% in the placebo group. To detect this difference with 90% power, 209 patients need to be included in the Cevira group and 105 patients in the placebo group using a 2:1 randomisation.

Patients, for whom the diagnosis for study enrolment was changed from HSIL to not HSIL on confirmation of the diagnosis by a panel of three expert gynaecological pathologists from three independent institutions, will be excluded from the primary efficacy analysis (modified intent-to-treat (mITT) population). Based on the phase 2b study results, an 8% error rate of pathological assessment and 10% dropout rate should be considered. Therefore, the total sample size needs to consist of at least 384 patients (256 in Cevira group and 128 in the placebo group). The aim is to enrol 300 patients in Chinese centres and 84 patients in centres in EU, Ukraine and Russia, with no recruitment goal for the sites.


### Statistical analysis plan

To avoid bias, the statistical analysis team will be required to remain blinded throughout the entire study period until primary database lock (primary analyses will be performed when all patients have either completed the 6-month assessments or are early terminated from the study).

The primary efficacy endpoint analysis will be performed on the mITT population and repeated on per protocol population, which is defined as the subset of patients in the mITT population who had no major protocol violations. Analysis will be done using the Cochran Mantel Haenszel test stratified by CIN diagnosis (CIN2 or CIN3) and HPV status (HPV-, HPV16+ and HPV18+Other+). Estimates and exact 95% CIs for the proportion of patients who achieve response will be calculated overall, for each treatment group, for each diagnosis group, for each HPV status group and for each diagnosis group by HPV status subgroup (ie, for each of the randomisation strata).

The secondary efficacy endpoints on mITT population will be analysed the same as described for the primary endpoint. The study extension endpoints will be summarised using counts and percentages for the extension population. The summary will be presented overall, by CIN diagnosis and by HPV status. The safety analysis will be performed on the safety population. If possible, a distinction will be made between Cevira 5% HAL ointment-related and Cevira CL7 device-related AEs.

Two sensitivity analyses will investigate the effect of missing data on the result of the primary endpoint analysis in the mITT population: analysis of all responder data as observed (ie, no imputations) and analysis after imputing all missing 6-month data as success (responders) in the



**Figure 3** Study flow and assessments of the APRICITY phase 3 study. \*Performed by telephone calls. \$Only treatment group. AEs, adverse events; FU, follow-up; HPV, human papilloma virus.

placebo treatment group and as failure (non-responders) in the Cevira treatment group. In the safety population, missing values will be treated as missing and will not be substituted.

#### Randomisation and blinding method

The patients will be randomised through an Interactive Web Response System (IWRS) after initial screening by the investigators. The IWRS will generate a randomisation number after the investigator inputs the required information and will then assign a product for the patient. The investigators, study personnel and patients are blinded to the treatment groups as Cevira and placebo products are identical in packaging. Additionally, the light signal before insertion does not differ between Cevira and placebo products. If during the blinded part of the study a medical emergency or SAE occurs and the patient's condition requires knowledge of the test medication, the study blind may be broken and reported for that specific patient. After the 6-month assessment, the planned unblinding procedure will be performed by the investigators to decide if patients will continue in the open-label extension study.

#### Data and study monitoring

An electronic data collection system will be used to collect and manage the trial data in this study. Patient data should be entered continuously during the study and within 48 hours after a visit is performed. As nonclinical local

tolerance studies and previous clinical studies showed an excellent safety profile with only mild to moderate local reactions and few related systemic side effects, no data monitoring committee is planned for this study. Nevertheless, all events occurring during the period of observation, reported spontaneously by the patient or elicited through open (non-leading) questioning during each visit, will be documented on the pages provided on the AE form in the electronic case report form (eCRF). Any SAEs for which a causal relationship to the treatment cannot be ruled out will be documented on the AE form even if they occur after the period of observation. Related AEs and SAEs should be followed up until resolved, or at the latest until database lock. In case of permanent impairment, the event must be followed until the condition stabilises and the investigator considered it medically justifiable to terminate follow-up, or at the latest until database lock.

Study monitoring will be performed in accordance with International Conference on Harmonization (ICH) E6-Good Clinical Practice (GCP)/ISO 14155:2020 as applicable, the sponsor/contract research organisation (CRO) standard operating procedures (SOPs), the protocol, the monitoring plan and applicable local regulations. If missing or inconsistent data not catered for are detected, queries will be issued. Queries may also be generated during the data validation process and shall be resolved immediately before database lock. All study documentation at the investigator site and sponsor site

will be archived in accordance with the ICH E6- GCP/ ISO 14155:2020 as applicable, EU Regulation 536/2014, 21 CFR 312.62, and the sponsor's quality standards and SOPs. An auditor authorised by the sponsor may audit the investigational site and request access to all source documents, eCRF and other study documentation.

### Patient and public involvement

Patients and general public were not involved in the design, conduct, reporting or dissemination plans of the presented study and did not assess the burden of participating in the study. Patients will receive HPV and colposcopy test results from their provider, as part of routine practice. All other study results will be disseminated to the participants on demand.

### ETHICS AND DISSEMINATION

The study was approved by the ethics committee of the Peking Union Medical College Hospital on 2 July 2020 (Nr. KS20202255). Current version of the protocol (number 2.2) from 31 July 2021 was also approved on 20 December 2021 by Hannover Medical University, Germany. It is conducted in accordance with the International Conference on Harmonization Guideline for Good Clinical Practice, the Declaration of Helsinki and all applicable national and international laws, regulations and standards, including archiving of essential documents. Patients agreeing to participate in the study must sign an informed consent form approved according to local regulations. The study site staff member conducting the consent process must also sign the consent form on the same occasion. All amendments to the clinical study protocol should be agreed on between the sponsor and the investigator and be recorded with a justification for the amendment. The only exceptions are, where necessary to eliminate an immediate hazard to study patients, or when the changes involve only administrative aspects of the study (eg, change in monitor(s), change of telephone number(s)). All information concerning drug/device and the sponsor's research and product development is considered confidential and will remain the sole property of the sponsor. A financial agreement will be signed between the sponsor and the investigators and/or the institution involved as required.

Final data analysis and disclosure of contractual agreements will be done by CRO Hangzhou Tigermed Consulting, which will limit the access of investigators to the final trial data set. The monitors, auditors, authorised personnel of the sponsor, health authority inspectors or their agents and authorised members of Independent Ethics Committees/Institutional Review Boards will be given direct access to the source data and documentation (eg, medical charts/records, laboratory results, printouts, videotapes and photographs) on request, provided that patient confidentiality is maintained in accordance with local requirements.

Findings of this study will be disseminated through peer review publications and conference presentations. No information which could lead to the identification of patients will be included in the dissemination of results.

### DISCUSSION

Cervical cancer is the most common HPV-related malignancy.<sup>5</sup> Given the substantial burden of cervical cancer globally, efforts have been made to develop effective prevention measures, including HPV vaccination and screening programmes in combination with timely and efficient treatment of precancerous lesions.<sup>2 9</sup> Unfortunately, these preventive measures are not equally implemented worldwide, with absent or inadequate screening and vaccination programmes in many low-income and middle-income countries who suffer the highest HPV incidence rates. Especially in Eastern Europe and Central Asia, a rapid increase in premature cervical cancer mortality has been reported in recent generations.<sup>2</sup> Furthermore, currently available vaccines are expensive and directed against only certain HPV subtypes.<sup>9 29</sup>

PDT has been clinically approved for the treatment of different cancers, including skin cancer, superficial oesophageal cancer and lung cancer.<sup>30–32</sup> Due to the lack of adequate non-surgical treatment modalities, the potential of PDT for the treatment of CIN has been investigated in this and previous studies.<sup>22–27 33</sup> The main advantage of PDT for the treatment of CIN is its non-invasiveness, leaving the cervix intact and thereby preserving fertility. Moreover, targeted PDT of CIN is not restricted by HPV subtype causing precancerous lesions and the PDT could be repeated in case of another infection or lesion.

For the treatment of CIN, topical administration of both 5-aminolaevulinic acid and its esterified derivate HAL have been studied, with HAL being preferred due to its better stability and increased fluorescence at lower doses leading to less systemic exposure.<sup>22 24 30</sup> As topical administration was perceived to be inconvenient, the integrated light-delivery and drug-delivery device Cevira was developed.<sup>23 27 33</sup> The safety and efficacy of Cevira have been evaluated in a double-blind, placebo-controlled dose-finding phase 2b study including 262 patients with CIN1/2 randomised to HAL 0.2%, 1% or 5% or placebo, permitting retreatment at 3 months if clinically indicated.<sup>27</sup> Based on the outcomes of the phase 2b, the HAL 5% dose was selected for further evaluation in the phase 3 study. The HAL 5% dose had a favourable safety profile while being associated with the highest regression rate and oncogenic HPV clearance. However, efficacy could only be demonstrated in patients with CIN2, probably due to a high rate of spontaneous regression in the CIN1 population with most patients being HPV negative. As a result, the present phase 3 study will only include HSIL patients (CIN2/3) ensuring efficacy can be reliably assessed. Due to the local and transient exposure to HAL, side effects were usually self-limiting, mainly including discharge, discomfort and spotting.





The currently available data indicate that Cevira is easy-to-use for gynaecologists and well accepted by patients.<sup>33</sup> The device results in no patient down-time as it is similar to using a tampon, patients may leave the gynaecologist office immediately after the application and can return to normal daily activities. Additionally, patients can easily remove the device themselves by pulling the string within 24 hours after application. The current phase 3 study will further evaluate how the use of Cevira device is perceived by gynaecologists and patients.

In summary, Cevira holds potential to serve high unmet medical need for non-surgical, safe treatment options for patients with HSIL and cervical cancer. Due to its non-invasiveness, Cevira could be a promising alternative to excisional treatment for young women in reproductive age. Following the encouraging results from the phase 2b study, the efficacy and safety of Cevira in patients with HSIL will be further evaluated in the presented APRICITY phase 3 study currently recruiting patients in China and Europe for a multicentre, prospective, double-blind randomised controlled clinical trial.

### Trial status

The APRICITY phase 3 study is currently recruiting patients in China, Ukraine, Russia and Europe. Recruitment started in November 2020 with the aim to enrol at least 384 patients. However, study start-up had to be delayed in Ukraine and Russia. In addition, the process might be interrupted or extended due to the COVID-19 pandemic.

### Author affiliations

<sup>1</sup>Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China

<sup>2</sup>Aranyklinika Gynecology, Budapest, Hungary

<sup>3</sup>Department of Gynaecology, National Institute of Oncology, Budapest, Hungary

<sup>4</sup>Department of Obstetrics and Gynaecology, University Hospital Augsburg, Augsburg, Germany

<sup>5</sup>MCM GYNPED, s.r.o, Dubnica nad Vahom, Slovakia

<sup>6</sup>Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

<sup>7</sup>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China

<sup>8</sup>Department of Obstetrics and Gynecology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China

<sup>9</sup>Asieris Pharmaceuticals (Shanghai) Co., Ltd, Shanghai, China

<sup>10</sup>Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany

<sup>11</sup>Comprehensive Cancer Center Niedersachsen, Hannover, Germany

**Acknowledgements** The authors are grateful to Ismar Healthcare NV who provided medical writing assistance on behalf of Shanghai Yahong MediTech Co., Ltd.

**Contributors** FC, LS, YZ, ZY, LH and PH contributed to the experimental design of the study. CD, ZN and CM were involved in study design, outcome definition and ethical approval application. JL is the global PI of the study. PH is the European PI of the study. FC is the Chinese PI of the study. All PIs have contributed to the study protocol amendments. All authors have read, edited and approved the manuscript.

**Funding** This study and support in the process of manuscript development were funded by Shanghai Yahong MediTech Co., Ltd, Pudong, Shanghai, China.

**Competing interests** CD received consulting fees from MSD, GSK, Tesaro and Clovis Oncology and honoraria from MSD and GSK. LH is an employee of Asieris

Pharmaceuticals (Shanghai) Co., Ltd. FC, ZN, CM, LS, YZ, ZY, JL and PH have nothing to declare.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

### ORCID iD

Peter Hillemanns <http://orcid.org/0000-0001-9829-3531>

### REFERENCES

- 1 Cervical cancer. Available: <https://www.who.int/health-topics/cervical-cancer>
- 2 Sung H, Ferlay J, Siegel RL, *et al*. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–49.
- 3 Castellsague X, de Sanjose S, Aguado T. World. *Vaccine* 2007;25:C1–26.
- 4 Bernard H-U, Burk RD, Chen Z, *et al*. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology* 2010;401:70–9.
- 5 Human papillomavirus (HPV) and cervical cancer. Available: [https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-\(hpv\)-and-cervical-cancer](https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer)
- 6 Gravitt P, Winer R. Natural history of HPV infection across the lifespan: role of viral latency. *Viruses* 2017;9:267.
- 7 Usyk M, Zolnik CP, Castle PE, *et al*. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. *PLoS Pathog* 2020;16:e1008376.
- 8 Khieu M, Butler SL. *High grade squamous intraepithelial Lesion. [Updated 2021 Jan 11]. In: StatPearls [online].* Treasure Island, FL: StatPearls Publishing, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK430728/>
- 9 Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. *Cancer Epidemiol Biomarkers Prev* 2013;22:553–60.
- 10 WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Available: <https://www.who.int/publications/i/item/9789240030824>
- 11 Tainio K, Athanasiou A, Tikkinen KAO, *et al*. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. *BMJ* 2018;360:k499.
- 12 Skorstengaard M, Lynge E, Suhr J, *et al*. Conservative management of women with cervical intraepithelial neoplasia grade 2 in Denmark: a cohort study. *BJOG: Int J Obstet Gy* 2020;127:729–36.
- 13 Perkins RB, Guido RS, Castle PE, *et al*. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. *J Low Genit Tract Dis* 2020;24:102–31.
- 14 Kyrgiou M, Athanasiou A, Kalliala IEJ, *et al*. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. *Cochrane Database Syst Rev* 2017;11:CD012847.
- 15 Duesing N, Schwarz J, Choschick M, *et al*. Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP). *Arch Gynecol Obstet* 2012;286:1549–54.
- 16 Arbyn M, Redman CWE, Verdoodt F, *et al*. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. *Lancet Oncol* 2017;18:1665–79.
- 17 Onuki M, Matsumoto K, Sakurai M, *et al*. Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis. *J Gynecol Oncol* 2016;27:e3.
- 18 Xiong Y, Cui L, Bian C, *et al*. Clearance of human papillomavirus infection in patients with cervical intraepithelial neoplasia: a systemic review and meta-analysis. *Medicine* 2020;99:e23155.
- 19 Desravines N, Miele K, Carlson R, *et al*. Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2-3: a narrative review. *Gynecol Oncol Rep* 2020;33:100608.



- 20 Dadar M, Chakraborty S, Dhama K, *et al.* Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus. *Front Immunol* 2018;9:2478.
- 21 Jordan J, Martin-Hirsch P, Arbyn M, *et al.* European guidelines for clinical management of abnormal cervical cytology, part 2. *Cytopathology* 2009;20:5–16.
- 22 Andrejevic-Blant S, Major A, Lüdicke F, *et al.* Time-dependent hexaminolevulinate induced protoporphyrin IX distribution after topical application in patients with cervical intraepithelial neoplasia: a fluorescence microscopy study. *Lasers Surg Med* 2004;35:276–83.
- 23 Hillemanns P, Einstein MH, Iversen OE. Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia. *Expert Opin Investig Drugs* 2015;24:273–81.
- 24 Hillemanns P, Wang X, Hertel H, *et al.* Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. *Am J Obstet Gynecol* 2008;198:300.e1–7.
- 25 Hillemanns P, Petry K-U, Soergel P, *et al.* Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia. *Lasers Surg Med* 2014;46:456–61.
- 26 Soergel P, Dahl GF, Onsrud M, *et al.* Photodynamic therapy of cervical intraepithelial neoplasia 1-3 and human papilloma virus (HMV) infection with methylaminolevulinate and hexaminolevulinate-a double-blind, dose-finding study. *Lasers Surg Med* 2012;44:468–74.
- 27 Hillemanns P, Garcia F, Petry KU, *et al.* A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. *Am J Obstet Gynecol* 2015;212:465.e1–7.
- 28 Soergel P, Loehr-Schulz R, Hillemanns M, *et al.* Effects of photodynamic therapy using topical applied hexylaminolevulinate and methylaminolevulinate upon the integrity of cervical epithelium. *Lasers Surg Med* 2010;42:784–90.
- 29 Kombe Kombe AJ, Li B, Zahid A, *et al.* Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. *Front Public Health* 2020;8:552028.
- 30 Shishkova N, Kuznetsova O, Berezov T. Photodynamic therapy for gynecological diseases and breast cancer. *Cancer Biol Med* 2012;9:9–17.
- 31 van Straten D, Mashayekhi V, de Bruijn HS, *et al.* Oncologic photodynamic therapy: basic principles, current clinical status and future directions. *Cancers* 2017;9:19.
- 32 Gunaydin G, Gedik ME, Ayan S. Photodynamic therapy for the treatment and diagnosis of cancer-a review of the current clinical status. *Front Chem* 2021;9:686303.
- 33 Einstein M, Sordal T, Lunde T. *Safety of hexaminolevulinate photodynamic therapy - a non-extirpative treatment for cervical neoplasia (CIN)*. San Francisco: ASCCP, 2012.